The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index

Breast Cancer Research and Treatment

Volumn 48, Issue 1, 1998, Pages 1-9

  Collett, K ^a,c   Skjaerven R ^b   Maehle B O ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Estrogen receptor status; Interaction effects; Progesterone receptor status; Prognostic index; Time dependency

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TIME; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; NORWAY; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; ROC CURVE; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031929274     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005945000264     Document Type: Article

References (32)

1. Miller WR, Ellis IO, Sainsbury JRC, Dixon JM: ABC of breast diseases. Prognostic factors. Br Med J 309: 1573-1576, 1994
2. Haybittle JL, Blarney RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K: A prognostic index in primary breast cancer. Br J Cancer 45: 361-366, 1982
3. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT: The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 32: 281-290, 1994
4. Uyterlinde AM, Baak JPA, Schipper NW, Peterse H, Matze E, Meijer CJL: Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer patients with long follow-up. Int J Cancer 45: 1-7, 1990
5. Baak JPA, Van Dop H, Kurver PHJ, Hermans J: The value of morphometry to classic prognosticators in breast cancer. Cancer 56: 374-382, 1985
6. Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E, Syrjänen K: Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer. Int J Cancer 49: 886-892, 1991
7. Mæhle BO, Thorescn S, Skjærven R, Hartveit F: Mean nuclear area and histological grade of axillary-node tumour in breast cancer, related to prognosis. Br J Cancer 46: 95-100, 1982
8. Baak JPA, Kurver PHJ, De Snoo-Niewlaat AJE, De Graef S, Makkink B, Boon ME: Prognostic indicators in breast cancer - morphometric methods. Histopathol 6: 327-339, 1982
9. Collett K, Hartveit K, Skjærven R, Mæhle BO: Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. J Clin Pathol 49: 920-925, 1996
10. Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gómez F: The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 57: 1171-1180, 1986
11. Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364-2367, 1981
12. Blamey RW, Bishop HM, Blake JRS, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K: Relationship between primary breast tumor receptor status and patient survival. Cancer 46: 2765-2769, 1980
13. Mathiesen O, Bonderup O, Carl J, Panduro J, Pedersen KO: The prognostic value of estrogen and progesterone receptors in female breast cancer. Acta Oncol 30: 691-695, 1991
14. Saez S, Cheix F, Mayer M: Estrogen and progesterone receptors as prognostic factors in early breast cancer. Rec Results Cancer Res 91: 192-198, 1984
15. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985-2990, 1983
16. Galea MH, Blamey RW, Elston CE, Ellis IO: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219, 1992
17. Dixon WJ: BMDP Statistical Software. Berkeley, University of California Press, 1990
18. Rothman KJ, Greenland S, Walker AM: Concepts of interaction. Am J Epidemiol 112: 467-470, 1980
19. Lupu R, Lippman ME: The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27: 83-93, 1993
20. Mittra IM, Redkar AA, Badwe RA: Prognosis of breast cancer: Evidence of interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 60: 106-111, 1995
21. Clark GM: Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven Publishers. Philadelphia, 1996, p 476
22. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990
23. Remvikos Y, Magdelenat H, Dutrillaux B: Genetic evolution of breast cancer III: Age-dependent variations in the correlations between biological indicators of prognosis. Breast Cancer Res Treat 34: 25-33, 1995
24. Fentiman IS, Cuzick J, Millis RR, Hayward JL: Which patients are cured of breast cancer? Br Med J 289: 1108-1111, 1984
25. Stenkvist B, Bengtsson E, Dahlqvist B, Eklund G, Eriksson O, Jarkrans T, Nordin B: Predicting breast cancer recurrence. Cancer 50: 2884-2893, 1982
26. Toikkanen SP, Kujari HP, Joensuu H: Factors predicting late mortality from breast cancer. Eur J Cancer 27: 586-591, 1991
27. Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E, Syrjänen K: Prognostic factors after 5 years of follow-up. Oncology 49: 93-98, 1992
28. Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87: 942-951, 1992
29. Zahl PH, Tretli S: Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 16: 1-15, 1997
30. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489-492, 1987
31. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-115, 71-85, 1992
32. Gundersen S, Hannisdal E, Søreide JA, Skarstein A, Varhaug JE: Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 36: 49-53, 1995